A First-in-Human Study Investigating BG-85738 Alone or in Combination With Other Antitumor Agents in Patients With Advanced or Metastatic Solid Tumors With Rat Sarcoma Virus (RAS) Mutations

The purpose of this study is to test if the BG-85738 is safe and if it works in patients with advanced solid tumors with RAS mutations when it is given on its own and in combination.

Trial Details

NCT ID
NCT07746141
Phase
PHASE1
Sponsor
BeOne Medicines
Status
RECRUITING
Cancer Type
Sarcoma
Interventions
  • BG-85738
  • Tislelizumab
  • Cetuximab
Locations (sample)
  • South Brisbane, Queensland, Australia|-27.48034,153.02049
  • Malvern, Victoria, Australia|-37.86259,145.02811
  • Auckland, New Zealand|-36.84853,174.76349

Key Eligibility Criteria

  • Participants are eligible to be included in the study only if they meet all the following criteria:
  • Participants must sign the informed consent form and be capable of giving written informed consent, which includes compliance with the requirements…
  • Participants must be ≥ 18 years of age (or the legal age of consent in the jurisdiction in which the study is taking place, whichever is older), at…
  • Participants with histologically or cytologically confirmed advanced, metastatic, and unresectable solid tumors and meet study part and cohort-spec…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Sarcoma Trials on Trialify →